Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
此前報道，第一三共和阿斯利康的ENHERTU顯示，HR陽性、HER2低轉移性乳腺癌的無進展存活率可達13.2個月
- DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful benefit for patients in this setting
- Additionally, data from DESTINY-Breast03 and DESTINY-Breast07 trials in HER2 positive metastatic breast cancer reinforce ENHERTU as standard of care in second-line setting and highlight potential in first-line setting
- Destiny-breast06結果顯示，第一三共和阿斯利康的ENHERTU是第一種在這種環境下爲患者顯示出具有臨床意義的益處的HER2定向藥物和抗體藥物偶聯物
- 此外，來自針對HER2陽性轉移性乳腺癌的Destiny-breast03和Destiny-breast07試驗的數據強化了ENHERTU作爲二線醫療標準的地位，也凸顯了一線環境中的潛力
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。